Annals of Oncology· @Annals_Oncology · X·· 23 小时前评分70
正文 · 原文
📢 #ESMO26 concomitant paper - Pembrolizumab plus chemotherapy for HR+/HER2− PD-L1‒positive advanced breast cancer: final analysis of the phase 3 KEYNOTE-B49 Study.
🔗https://tinyurl.com/3xrc9ycw
@hoperugo
174 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Annals of Oncology · x.com